Daniel M Girardi

6PUBLICATIONS
77CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Chemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 17, 2026
Tumor regression pattern and distribution of residual tumor cells in potential candidates for local excision of rectal cancer: a prospective cohort study.

|Jul 02, 2024
Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors.

Andrea B Apolo, Daniel M Girardi, Scot A Niglio

|Apr 09, 2024
Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update.

Andrey Soares, Fernando Sabino Marques Monteiro, Karine Martins da Trindade

|Jan 15, 2022
Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy.

Daniel M Girardi, Scot A Niglio, Amir Mortazavi

|Sep 11, 2020
Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors.

Andrea B Apolo, Rosa Nadal, Daniel M Girardi

|Sep 04, 2018
Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?

Daniel M Girardi, Luiza Dib B B Faria, Marcela C Teixeira

Pageof 1

Frequent Collaborators

3 joint publications

Amir Mortazavi

3 joint publications

Donald P Bottaro

3 joint publications

Seth M Steinberg

3 joint publications

Rosa Nadal